license for Iranian recombinant COVID vaccine
license for Iranian recombinant COVID vaccine
An official with the Ministry of Health said that a clinical trial of phase one of recombinant coronavirus vaccine belonging to Razi Vaccine & Serum Research Institute was approved.

TEHRAN (Iran News) – Secretary of National Research Ethics Committee of the Health Ministry, Ehsan Shamsi Goshki broke the news on Monday and added, “The most important step was taken to start the clinical trial of the second Iranian COVID-19 vaccine and Iranian Food and Drug Administration (IFDA) will soon issue a license for the clinical trial permit.”

After the issuance of the first clinical trial license for coronavirus vaccine, belonging to Barakat Pharmaceutical Group Company and Shifa Daroo Pharmaceutical Company, a license for conducting a phase 1 clinical trial for COVID-19 vaccine produced by Razi Vaccine and Serum Research Institute has also been issued in the Ethics Committee, he continued.

Shamsi went on to say that one of the members of the Ethics Committee is present during the clinical trial as a member of the Data Monitoring Committee and will monitor the proper conduct of the research process.

This recombinant vaccine is a recombinant protein whose technology and is different from the previous licensed Iranian COVID-19 vaccine (inactivated virus), he said, adding, “ The clinical trial of the second Iranian coronavirus vaccine will be conducted by Razi Serum and Vaccine Institute in cooperation with Iran University of Medical Sciences.”

The first phase of clinical studies of human injection of the first COVID vaccine made by Iranian researchers called ‘COVO-Iran Barakat’ was performed on the volunteers on Tuesday (December 29) in the presence of the minister of health and medical education and the vice president for science and technology.

Several other research centers and institutes and knowledge-based companies are trying to make an Iranian COVID vaccine, which has achieved good results in this field.

In addition, to live vectored and inactivated viruses, novel recombinant technologies are being used in the development of the COVID-19 vaccine. The advantage of recombinant vaccines is their greater response predictability and improved efficacy.

  • source : Mehr